JUL 31, 2018 08:25 PM PDT

Pill Approved For Endometriosis Treatment

WRITTEN BY: Nouran Amin

A first drug, by the name of Elagolix, to treat for endometriosis-related pain, has recently become approved by the US Food and Drug Administration. Endometriosis is caused by uterine tissue moving to another part of the body, usually around the pelvis. The pain, which affects one in ten young women, can cause severe pelvic discomfort during menstruation, sexual intercourse, or all the time. Currently, endometriosis-related pain is managed by common painkillers, contraceptives that work to lessen or block menstruation, or through injectable hormonal treatments. In many cases, women suffering from endometriosis do not benefit from these treatments because they either don’t work, produce unpleasant side-effects such as weight gain or moodiness, or administered for only short periods of time due to the effects of the treatment on bone density.

Fortunately, Elagolix may be taken for longer, but it does come with several side-effects. During a placebo-controlled clinical trial study that examined almost 900 women with moderate to severe endometriosis pain, Elagolix was seen to reduce menstrual pain in over 40 percent of affected women and non-menstrual pelvic pain in over 50 percent when taken orally as a once-daily pill. Elagolix was also seen to reduce average pain ratings during sexual intercourse. The science of Elagolix works by reducing estrogen, the hormone that drives endometriosis. It is believed that because Elagolix slightly reduces the estrogen levels, the drug can be taken for up to two years. On the other hand, injectable hormone treatments, which effectively lower estrogen more powerfully, can only be administered for 6 months because it causes bone loss.

The side-effects that come with taking Elagolix include hot flushes and headaches in about 20 percent of the patient’s examined in the clinical trial with nausea occurring in about 10 percent. “Despite these side-effects, any extra options for treating endometriosis are welcome,” says Elizabeth Farrell, a gynecologist at Jean Hailes, an Australian women’s health organization. Farrell believes that despite the effectiveness of Elagolix, it is unlikely that it will become a first-line treatment for patients. “The oral contraceptive pill or an IUD would probably still be the first thing you tried,” she says.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2018
Drug Discovery
NOV 13, 2018
Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful
Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures...
DEC 17, 2018
Drug Discovery
DEC 17, 2018
Alzheimer Preventing Drug Could Work Like A Vaccine
Researchers at UT Southwestern believe that a protein called ApoE is the primary factor in late-onset Alzheimer's disease. Such conclusion has to inspi...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Super-Drug for Pediatric Leukemia?
In a final study published in Genes & Development, researchers at Northwestern University School of Medicine concluded their discoveries on two success...
JAN 14, 2019
Drug Discovery
JAN 14, 2019
Vitamin D Proved Non-Beneficial for Individuals Aged 70 and Over
According to a study in the American Journal of Clinical Nutrition, researchers at Newcastle University have confirmed that older individuals, over the age...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Slows Cancer's Circadian Clock
According to a study done on human kidney cancer cells and acute myeloid leukemia cells in mice, a compound was examined to halt the cancerous growth by st...
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Bodybuilding Supplement Harms Brain Cells
Researchers at University of Technology Sydney warn that the protein supplement, L-norvaline, could damage brain cells. The study was published in Toxicolo...
Loading Comments...